On this light, we have previously demonstrated that lanreotide can increase the activity of IL-2-activated peripheral blood mononuclear cells against a cellular model of NET of the thyroid, the medullary thyroid carcinoma (MTC) TT cell line. The gene discussed is IL2; the disease is medullary thyroid gland carcinoma.